Melanoma

Biologically Targeted Therapeutics

Inbunden, Engelska, 2002

709 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Strategies of treatment involving therapeutic proteins, irnrnune immune cells, or cel lular protein targets are those of greatest potential for further reducing mortality from melanoma. Therapeutic proteins or cells may inhibit melanoma cell growth either by augmentation of immune cell function or by inhibition of angiogenesis. Cytokines and melanoma antigens may be used either in vivo as a vaccine to stimulate irnrnune immune cell cell function or ex vivo to stimulate or proliferate cells for infusion. Alternatively, alteration in melanoma cell growth can occur through inhibition of protein signal transduction pathways within melanoma cells or in the endothelial cells constituting the necessary angiogenic support for tumor growth. The great promise of these therapies and their cellular targets constitutes the basis for Melanoma: Biologically Targeted Therapeutics. THE CLINlCAL PROBLEM More than four million people will be diagnosed with melanoma in the first decade of the 21st century. Half of those who will die will be individuals who would otherwise have had a life expectancy of another 25 years or more. These individuals will die of systemic systernic metastases, which are present at the time of primary surgery. Despite use of sunscreens, incidence continues to increase in developed countries worldwide. To reduce mortality, there must continue to be a focus on prevention and earlier detection through public education. Early interventions are always preferable to treatment of disseminated metastatic disease.

Produktinformation

Utgivningsdatum2002-04-03
Mått178 x 225 x undefined mm
FormatInbunden
SpråkEngelska
SerieCurrent Clinical Oncology
Antal sidor388
FörlagHumana Press Inc.
ISBN9780896038769

Tillhör följande kategorier

Onkologi inom Medicin

I Perspective on the Clinical Disease.- 1 Management of Primary Malignant Melanoma.- 2 A Pathologist’s Perspective on Prognostic Featuresof Malignant Melanoma.- 3 Clinical Prognostic Factors and Staging.- II Biological and Targeted Therapeutics.- 4 Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression.- 5 Immunotherapy of Advanced Melanoma Directed at Specific Antigens.- 6 Melanoma Antigens: Vaccines and Monoclonal Antibodies.- 7 Interleukin-2.- 8 Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma.- 9 Interferons: Preclinical and Clinical Studies in Melanoma.- 10 Biochemotherapy of Melanoma.- 11 Signal Transduction Abnormalities as Therapeutic Targets.- 12 Tumor Angiogenesis.- 13 Antiangiogenic Therapy for Melanoma.

"Incredible detail to immunologic mechanisms is the strong point of the book. The bibliography at the end of each chapter is exhaustive, sometimes citing over 300 references.The pharmacokinetics of cytokines are meticulously discussed and diagrammed. Tables summarizing the results of clinical trials to date are peppered throughout the book. The authors are careful not to draw conclusions that do not have support from prospective randomized clinical trials. It is an excellent source to become familiar with current research and experimental protocols for advanced melanoma. Researchers and directors of melanoma clinics at tertiary care facilities will want to have this book as a resource."-Weighted Numerical Score: 100 - 5 Stars!-Doody's Health S ciences Book Review Journal